The final three Paroxysmal Nocturnal Hemoglobinuria (PNH) patients enrolled into the Phase II COBALT trial with the revised dosing regimen had median LDH of …
Akari Therapeutics Strengthens Board with Two Senior Industry Appointments
NEW YORK and LONDON, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc(NASDAQ:AKTX) (“Akari” or “the Company”), a biopharmaceutical company focused on …
[Read more...] about Akari Therapeutics Strengthens Board with Two Senior Industry Appointments
Akari Therapeutics Announces Phase II COBALT trial of Coversin™ in Patients with PNH Met the Primary Endpoint
Last three patients enrolled into the Phase II COBALT trial on the new dosing regimen (45 mg per Day) saw a more rapid decline in LDH than those in the original …
Akari Therapeutics Announces Pricing of Public Offering of American Depositary Shares
NEW YORK and LONDON (GLOBE NEWSWIRE) October 18, 2017 / Akari Therapeutics, Plc (NASDAQ: AKTX), a biopharmaceutical company focused on the development and …
Akari Therapeutics Announces Proposed Public Offering of American Depositary Shares
NEW YORK and LONDON, October 17, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ: AKTX), a biopharmaceutical company focused on the development and …
